Rongshi Li, Ph.D.

Professor

Department of Pharmaceutical Sciences
College of Pharmacy
University of Nebraska Medical Center
985965 Nebraska Medical Center
Omaha, NE 68198-5965
402-559-6609 (Office)
402-559-9543
Lab DRC II, Room 6018
402-559-6521 (Lab)
rongshi.li@unmc.edu

Research Activities/Interests:
Dr. Li’s research focuses on fragment-based and structure-guided design of enzyme inhibitors and protein-protein interaction disruptors; hit-to-lead optimization using natural products chemistry and high-throughput medicinal chemistry; drug design and development in anticancer and anti-infective therapeutics.

Recent Publications:

  1. Patel, R.A.; Liu, Y.; Wang, B.; Li, R.; Sebti, S.M. Identification of Novel ROCK Inhibitors with Anti-migratory and Anti-invasive Activities. Oncogene, 2013, Feb. 11, (a featured article on www.MDLinx.com) Epub ahead of print. Pubmedid: 23396364. (Impact Factor: 7.357)
  2. Cheng, C.; Liu, Y.; Song, H.; Pan, L.; Li, J.; Qin, Y.; Li, R.* Marinopyrrole Derivatives as Potential Antibiotic Agents against Methicillin-Resistant Staphylococcus aureus (II). Mar. Drugs 2013, 11, 2927-2948. (Impact Factor: 3.978)
  3. Ziarek, J.J.; Liu, Y.; Smith, E.; Zhang, G.; Peterson, F.C.; Chen, J.; Yu, Y.; Chen, Y. Volkman, B.F.; Li, R.* Fragment-based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction. Curr. Top. Med. Chem. 2012, 12, 2727-2740. Pubmedid: 23368099. (Impact Factor: 4.174)
  4. Li, R.*; Martin, M.P.; Liu, Y.; Wang, B.; Patel, R.A.; Sun, N.; Pireddu, R.; Lawrence, N.J.; Li, J.; Haura, E.B.; Sung, S.S.; Guida, W.C.; Schonbrunn, E.; Sebti, S.M. Fragment-based and Structure-guided Discovery and Optimization of Rho Kinase Inhibitors. J. Med. Chem. 2012, 55, 2474-2478. Pubmedid: 22272748. (Impact Factor: 5.614)
  5. Liu, Y.; Haste, N.M.; Thienphrapa, W.; Nizet, V.; Hensler, M.; Li, R.* Marinopyrrole Derivatives as Potential Antibiotic Agents against Methicillin-Resistant Staphylococcus aureus (I). Mar. Drugs 2012, 10, 953-962. Pubmedid: 22690153. PMCID: PMC3366685. (Impact Factor: 3.978)
  6. Doi, K.; Li, R.; Sung, S.S.; Wu, H.; Liu, Y.; Manieri, W.; Gowdahalli, K.; Awwad, A.; Dewey, A.; Liu, X.; Amin, S.; Cheng, C.; Qin, Y.; Schonbrunn, E.; Daughdrill, G.; Loughran Jr, T.P.; Sebti, S.M.; Wang, H.G. Discovery of Marinopyrrole A (Maritoclax) a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation. J. Biol. Chem. 2012, 287, 10224-10235. Pubmedid: 22311987. Pmcid: PMC3323047. (Impact Factor: 4.773)
  7. He, S.M.; Li, R.; Kanwar, J.R.; Zhou, S.F. Structural and Functional Properties of Human Multidrug Resistance Protein 1 (MRP1/ABCC1). Curr. Med. Chem. 2011, 18, 439-481. Pubmedid: 21143116. (Impact Factor: 4.859)
  8. Cheng, C.; Pan, L.; Chen, Y.; Song, H.; Qin, Y.; Li, R.* Total Synthesis of (±)-Marinopyrrole A and Its Library as Potential Antibiotic and Anti-cancer Agents. J. Comb. Chem. 2010, 12, 541-547. Pubmedid: 20429575. (Impact Factor: 3.408)
  9. Li, R.*; Pourpak, A.; Morris, S. W. Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach.  J. Med. Chem. 2009, 52, 4981-5004. (One of 10 Most-Accessed Articles, July-Sept. 2009). Pubmedid: 19610618. Pmcid: PMC2888655. (Impact Factor: 5.248)
  10. Li, R.*; Morris, S. W. Development of Anaplastic Lymphoma Kinase (ALK) Small-Molecule Inhibitors for Cancer Therapy.  Med. Res. Rev. 2008, 28, 372-412. Pubmedid: 17694547. (Impact Factor: 10.7)
    

Rongshi Li, Ph.D.
Dr. Li
;